BioCryst Pharmaceuticals (BCRX) stock plummeted 7.17% in the pre-market session on Monday, following the company's release of its fourth quarter and full year 2024 financial results. The biotechnology firm missed analyst estimates for Q4 earnings, even as it reported strong revenue growth driven by its flagship drug ORLADEYO.
For the fourth quarter, BioCryst reported revenue of $131.5 million, a 40.8% increase from the prior year period, with ORLADEYO contributing $124.2 million. However, the company reported a net loss of $26.8 million or $0.13 per share, missing analyst expectations of a $0.06 loss per share. For the full year 2024, BioCryst's revenue surged 36% to $450.7 million, with ORLADEYO sales reaching $437.7 million, but the company posted a net loss of $88.9 million or $0.43 per share.
Looking ahead, BioCryst raised its 2025 ORLADEYO net revenue guidance to between $535 million and $550 million, up from its previous range of $515 million to $535 million. The company expects to approach positive earnings per share and positive cash flow in the second half of 2025, and aims to achieve meaningful and sustainable profitability in 2026. Additionally, BioCryst is advancing its pipeline candidates, including seeking label expansion for ORLADEYO in pediatric patients and advancing therapies for rare diseases such as Netherton syndrome and diabetic macular edema.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.